Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...

The American Board of Regenerative Medicine has endorsed AEON Clinic, the first regenerative wellness facility in the Middle East, today unveiled its whole ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

Dr Marc Laniado made a choice to be more mindful of his own health - here's what he discovered, from 'exercise snacking' to ...

The calls to 911 poured in from staff at Camp East Montana, the nation's largest U.S. Immigration and Customs Enforcement detention facility, in its first months of operation in El Paso, Texas.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...